Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
0.224
-0.014 (-5.68%)
At close: Apr 28, 2026, 4:00 PM EDT
0.225
+0.001 (0.22%)
After-hours: Apr 28, 2026, 4:42 PM EDT
Calidi Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | - | - | - | 0.05 | 0.45 | |
| Revenue Growth (YoY) | - | - | - | -89.98% | - | |
| Cost of Revenue | - | - | - | 0.01 | 0.09 | |
| Gross Profit | - | - | - | 0.03 | 0.36 | |
| Selling, General & Admin | 10.5 | 12.9 | 15.98 | 15.9 | 6.16 | |
| Research & Development | 9.74 | 8.88 | 13.01 | 7.26 | 3.8 | |
| Operating Expenses | 20.24 | 21.78 | 28.99 | 23.16 | 9.96 | |
| Operating Income | -20.24 | -21.78 | -28.99 | -23.13 | -9.61 | |
| Interest Expense | -0.31 | -1.63 | -1.07 | -0.16 | -0.61 | |
| Other Non Operating Income (Expenses) | 0.26 | 1.21 | 1.33 | -2.13 | 0.24 | |
| EBT Excluding Unusual Items | -20.29 | -22.2 | -28.73 | -25.42 | -9.98 | |
| Gain (Loss) on Sale of Investments | 0.24 | - | - | - | - | |
| Other Unusual Items | - | - | -0.47 | - | -0.06 | |
| Pretax Income | -20.05 | -22.2 | -29.2 | -25.42 | -10.92 | |
| Income Tax Expense | 0.02 | 0.01 | 0.02 | 0.01 | 0.01 | |
| Earnings From Continuing Operations | -20.06 | -22.21 | -29.22 | -25.43 | -10.93 | |
| Minority Interest in Earnings | 0.16 | 0.07 | - | - | - | |
| Net Income | -19.91 | -22.14 | -29.22 | -25.43 | -10.93 | |
| Preferred Dividends & Other Adjustments | 5.67 | 1.67 | - | - | - | |
| Net Income to Common | -25.58 | -23.81 | -29.22 | -25.43 | -10.93 | |
| Shares Outstanding (Basic) | 4 | 1 | 0 | 0 | 0 | |
| Shares Outstanding (Diluted) | 4 | 1 | 0 | 0 | 0 | |
| Shares Change (YoY) | 544.98% | 374.75% | 98.24% | -56.93% | 15.26% | |
| EPS (Basic) | -5.95 | -35.70 | -207.95 | -358.77 | -66.44 | |
| EPS (Diluted) | -5.95 | -35.70 | -207.95 | -358.77 | -66.44 | |
| Free Cash Flow | -21.41 | -19.71 | -27.57 | -13.64 | -7.98 | |
| Free Cash Flow Per Share | -4.98 | -29.55 | -196.22 | -192.49 | -48.49 | |
| Gross Margin | - | - | - | 68.89% | 79.06% | |
| Operating Margin | - | - | - | -51395.56% | -2139.42% | |
| Profit Margin | - | - | - | -56504.44% | -2434.97% | |
| Free Cash Flow Margin | - | - | - | -30315.56% | -1777.28% | |
| EBITDA | -18.59 | -20.24 | -28.6 | -22.87 | -9.45 | |
| D&A For EBITDA | 1.65 | 1.54 | 0.39 | 0.26 | 0.16 | |
| EBIT | -20.24 | -21.78 | -28.99 | -23.13 | -9.61 | |
| Revenue as Reported | - | - | - | 0.05 | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.